RU2631655C2 - Пирролопиримидиновые соединения для лечения злокачественной опухоли - Google Patents

Пирролопиримидиновые соединения для лечения злокачественной опухоли Download PDF

Info

Publication number
RU2631655C2
RU2631655C2 RU2014115847A RU2014115847A RU2631655C2 RU 2631655 C2 RU2631655 C2 RU 2631655C2 RU 2014115847 A RU2014115847 A RU 2014115847A RU 2014115847 A RU2014115847 A RU 2014115847A RU 2631655 C2 RU2631655 C2 RU 2631655C2
Authority
RU
Russia
Prior art keywords
alkyl
group
compound according
mmol
pyrrolo
Prior art date
Application number
RU2014115847A
Other languages
English (en)
Russian (ru)
Other versions
RU2014115847A (ru
Inventor
Ксяодонг Ванг
Джинг ЛЮ
Вейхе ЗХАНГ
Стивен ФРИЕ
Дмитрий КИРЕЕВ
Original Assignee
Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл filed Critical Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл
Publication of RU2014115847A publication Critical patent/RU2014115847A/ru
Application granted granted Critical
Publication of RU2631655C2 publication Critical patent/RU2631655C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2014115847A 2011-10-03 2012-10-01 Пирролопиримидиновые соединения для лечения злокачественной опухоли RU2631655C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161542392P 2011-10-03 2011-10-03
US61/542,392 2011-10-03
US201161547183P 2011-10-14 2011-10-14
US61/547,183 2011-10-14
PCT/US2012/058298 WO2013052417A1 (en) 2011-10-03 2012-10-01 Pyrrolopyrimidine compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
RU2014115847A RU2014115847A (ru) 2015-11-10
RU2631655C2 true RU2631655C2 (ru) 2017-09-26

Family

ID=48044101

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014115847A RU2631655C2 (ru) 2011-10-03 2012-10-01 Пирролопиримидиновые соединения для лечения злокачественной опухоли

Country Status (13)

Country Link
US (3) US9273056B2 (enExample)
EP (1) EP2763988B1 (enExample)
JP (2) JP2014532060A (enExample)
KR (1) KR102063098B1 (enExample)
CN (1) CN103958510B (enExample)
AU (1) AU2012318896B2 (enExample)
BR (1) BR112014007788A2 (enExample)
CA (1) CA2850617A1 (enExample)
ES (1) ES2650630T3 (enExample)
IL (1) IL231835A0 (enExample)
MX (1) MX2014004086A (enExample)
RU (1) RU2631655C2 (enExample)
WO (1) WO2013052417A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2829484C2 (ru) * 2016-09-16 2024-10-30 ВИТЭ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Ингибиторы взаимодействия менин-mll

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
JP2015517574A (ja) 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2014018535A1 (en) 2012-07-25 2014-01-30 Salk Institute For Biological Studies Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9649309B2 (en) 2014-04-11 2017-05-16 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) * 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
WO2017062797A1 (en) * 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill The methods for treatment of tumors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
CN110177553A (zh) * 2016-11-17 2019-08-27 北卡罗来纳大学教堂山分校 烷基吡咯并嘧啶类似物及其制备和使用方法
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
WO2019133629A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
KR102163494B1 (ko) * 2018-10-26 2020-10-08 한국과학기술연구원 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체
US12275737B2 (en) 2019-04-02 2025-04-15 Meryx, Inc. Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN112043710A (zh) * 2020-09-28 2020-12-08 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
CN115073469B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物作为激酶抑制剂的制备及其应用
WO2025170773A1 (en) * 2024-01-26 2025-08-14 The University Of North Carolina At Chapel Hill Tam-family degraders and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
RU2305682C2 (ru) * 2001-05-14 2007-09-10 Новартис Аг Производные 4-амино-5-фенил-7- циклобутилпирроло[2,3-d]пиримидина
US20070225306A1 (en) * 2004-02-14 2007-09-27 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
WO2010043865A1 (en) * 2008-10-17 2010-04-22 Chroma Therapeutics Ltd Inhibitors of hsp90
WO2010117425A1 (en) * 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2011029915A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US7217710B2 (en) 2001-10-02 2007-05-15 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE602004012559T2 (de) 2003-05-28 2009-04-30 Universita Degli Studi Di Siena 4-SUBSTITUIERTE DERIVATE VON PYRAZOLOi3,4-D PYRIMIDIN UND DEREN VERWENDUNGEN
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0320728D0 (en) 2003-09-04 2003-10-08 Kilminster Shaun Test
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
JP5520433B2 (ja) 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
JP4790703B2 (ja) * 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8575342B2 (en) 2004-09-30 2013-11-05 Tibotech Pharmaceuticals Ltd. HIV inhibiting 5-heterocyclyl pyrimidines
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
AU2007233737B2 (en) 2006-03-30 2012-11-29 Janssen Sciences Ireland Uc HIV inhibiting 5-amido substituted pyrimidines
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
CA2703519C (en) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
EP2640392B1 (en) 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
MD20140023A2 (ro) * 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
BR112014021065A8 (pt) 2012-02-21 2018-04-24 Centre Nat Rech Scient receptores tam como cofatores de entrada do vírus
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
JP2015517574A (ja) 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2015153978A1 (en) 2014-04-04 2015-10-08 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
US9649309B2 (en) 2014-04-11 2017-05-16 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
RU2305682C2 (ru) * 2001-05-14 2007-09-10 Новартис Аг Производные 4-амино-5-фенил-7- циклобутилпирроло[2,3-d]пиримидина
US20070225306A1 (en) * 2004-02-14 2007-09-27 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2010043865A1 (en) * 2008-10-17 2010-04-22 Chroma Therapeutics Ltd Inhibitors of hsp90
WO2010117425A1 (en) * 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2011029915A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
& EA201200471. *
& US 2007105874 A1. *
Aso, Kazuyoshi; et al., Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor, Bioorganic & Medicinal Chemistry Letters (15.04.2011), 21(8), 2365-2371 (referat, найдено Online! ACS on STN, 154:588857 CA). *
EA201200471. *
US 2007105874 A1. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2829484C2 (ru) * 2016-09-16 2024-10-30 ВИТЭ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Ингибиторы взаимодействия менин-mll

Also Published As

Publication number Publication date
US9273056B2 (en) 2016-03-01
US20140243315A1 (en) 2014-08-28
US10179133B2 (en) 2019-01-15
AU2012318896A1 (en) 2014-05-22
CN103958510A (zh) 2014-07-30
US20160151372A1 (en) 2016-06-02
ES2650630T3 (es) 2018-01-19
US9795606B2 (en) 2017-10-24
CN103958510B (zh) 2016-10-19
JP2014532060A (ja) 2014-12-04
JP2017101043A (ja) 2017-06-08
KR20140095471A (ko) 2014-08-01
CA2850617A1 (en) 2013-04-11
BR112014007788A2 (pt) 2017-04-18
EP2763988A1 (en) 2014-08-13
EP2763988A4 (en) 2015-06-03
HK1201256A1 (en) 2015-08-28
JP6316925B2 (ja) 2018-04-25
MX2014004086A (es) 2014-09-22
RU2014115847A (ru) 2015-11-10
KR102063098B1 (ko) 2020-01-08
US20180104247A1 (en) 2018-04-19
AU2012318896B2 (en) 2017-03-02
EP2763988B1 (en) 2017-09-20
IL231835A0 (en) 2014-05-28
WO2013052417A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
JP6316925B2 (ja) 癌を治療するためのピロロピリミジン化合物
US9744172B2 (en) Pyrazolopyrimidine compounds for the treatment of cancer
AU2013266438B2 (en) Pyrimidine compounds for the treatment of cancer
US9562047B2 (en) Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) Pyrimidine compounds for the treatment of cancer
US20080319044A1 (en) Compounds and Methods of Use Thereof
JP2008520713A (ja) キナーゼ阻害剤
US20080269204A1 (en) Compounds and Methods of Use Thereof
US20090005344A1 (en) Compounds and Methods of Use Thereof
HK1201256B (en) Pyrrolopyrimidine compounds for the treatment of cancer
WO2006063010A2 (en) Compounds and methods of use thereof